Alto Neuroscience Reports Q3 GAAP EPS of -$0.54, Exceeding Estimates
Alto Neuroscience (NYSE: ANRO) reported third-quarter GAAP earnings per share of -$0.54, surpassing analyst expectations by $0.13. Despite the net loss, the company demonstrated a significant strengthening of its balance sheet during the period. The company's cash position grew substantially to approximately $319.8 million as of September 30, 2026, up from $177.0 million at the end of 2025. Management stated that this liquidity is expected to fund planned operations through 2030. Additionally, the company announced the promotion of Nick Smith to the role of President and CFO.
Tickers: $ANRO